证券时报·数据宝以股权变动日为基准进行统计，近5个交易日（1月5日~1月9日）共有13家公司股份获 重要股东增持，累计增持数量达3376.08万股，增持金额合计4.02亿元。同期共有163家公司重要股东涉 及减持，合计减持金额154.80亿元。 从增持金额看，近5日增持金额在千万元以上的有8家，增持金额最多的是万润股份，其间累计增持 750.42万股，增持金额合计1.14亿元；其次是同济科技，增持量为562.11万股，增持金额7476.06万元； 奥飞数据近5日获股东增持5454.55万元，增持金额位居第三。 板块分布显示，近5个交易日重要股东增持股中，创业板有3只，主板包含9只，增持金额上，创业板增 持7408.23万元，主板增持3.16亿元。 市场表现方面，获股东增持个股近5日平均上涨7.47%，整体强于其间沪指表现。从个股看，近5日涨幅 居前的有奥飞数据、生物股份、恒实科技等，涨幅分别为23.58%、15.46%、13.70%。跌幅居前的有恒 逸石化、华贸物流等，分别下跌2.60%、0.82%。 从资金流向看，股东增持股中，近5日主力资金净流入的有8只，净流入资金最多的是生物股份，合计净 流入资金0.6 ...

Group 1: Company Overview - The report focuses on Bio Co., Ltd. (600201), highlighting its potential breakthrough with the African Swine Fever vaccine, which is expected to reshape its competitive advantage and growth momentum [3][4]. - The recommendation logic emphasizes the company's strong R&D barriers, rich product pipeline, and the recent clinical approval of the ASF vaccine, which could become the main growth driver over the next 3-5 years [3][4]. Group 2: Financial Projections - Projected revenues for Bio Co., Ltd. from 2025 to 2027 are estimated at 1,603.76 million, 2,035.36 million, and 2,520.85 million yuan, with year-on-year growth rates of 27.74%, 26.91%, and 24.85% respectively [4]. - The net profit attributable to the parent company is forecasted to be 303.45 million, 397.65 million, and 491.31 million yuan for the same period, with growth rates of 178.44%, 31.04%, and 23.55% respectively [4]. Group 3: Catalysts and Drivers - Key catalysts include breakthroughs in the ASF vaccine development and advancements in the mRNA vaccine for feline infectious peritonitis [4]. - The driving factors for growth are the leading progress in ASF vaccine development, a solid position in foot-and-mouth disease, rapid expansion in the pet sector, and ongoing overseas market development [3][4]. Group 4: Market Position and Strategy - The company is expected to exceed performance expectations due to the clinical approval of the ASF vaccine, diversified product launches, and rapid overseas market expansion [3]. - The strategy includes leveraging marketing support, online channel development, and international market penetration to drive revenue growth [3].

Core Logic - The company has strong R&D barriers and a rich pipeline of new products, with the non-epidemic vaccine having received clinical approval, which could become the largest growth engine in the next 3-5 years if progress is smooth [1] Industry Dynamics - The animal health sector is expected to maintain a volume increase but price decrease trend due to weak recovery in the breeding industry and profit compression, with overall gross margins declining amid intense competition and product homogenization [2] Product Development - The company is a leader in the foot-and-mouth disease vaccine market, transitioning its core product logic to the subunit non-epidemic vaccine, which has a broad market potential. The market size is expected to reach 1.75 billion yuan in the first year and 3.5 billion yuan in the second year post-launch. The subunit non-epidemic vaccine is set to enter clinical trials in July 2025, with potential revenue contributions starting from late 2027 to early 2028 [3] Marketing Strategy - The company focuses on "big products + big clients," providing comprehensive solutions and building a multi-layered marketing system. Online and overseas market expansions are showing initial success, with pet direct sales increasing over fourfold year-on-year in the first half of 2025. The company has registered sales of foot-and-mouth products in countries like Pakistan and Vietnam, with plans for deeper market penetration in Mongolia and Central Asia [4] Financial Forecast - The company expects overall revenue of 1.604 billion, 2.035 billion, and 2.521 billion yuan for 2025-2027, with year-on-year growth rates of 27.74%, 26.91%, and 23.85%. The net profit attributable to shareholders is projected to be 304 million, 398 million, and 491 million yuan, with growth rates of 178.44%, 31.04%, and 23.55%, corresponding to P/E ratios of 64, 49, and 39 times [5]

农林牧渔 2026 年 01 月 11 日 | 陈雪丽（分析师） | 王高展（分析师） | | --- | --- | | chenxueli@kysec.cn | wanggaozhan@kysec.cn | | 证书编号：S0790520030001 | 证书编号：S0790525070003 | 周观察：春节备货尚未启动，下游利润仍待修复 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-01 2025-05 2025-09 农林牧渔 沪深300 相关研究报告 《牛肉进口"国别配额及配额外加征 关税"落地，利多国内牛价—行业周 报》-2026.1.4 《肥猪供给偏紧年前猪价上行，宠物 食品出口环比改善 —行业周报》- 2025.12.28 《年前猪价存在供需双重支撑，蛋鸡 存栏高位淘鸡延续 —行业周报》- 2025.12.21 10 春节备货尚未启动，下游利润仍待修复 ——行业周报 行 业 周 报 本周猪价小幅回落但屠宰量维持高位，二育进场积极性抬升，春节备货尚未启 动下游利润仍待修复。据涌益咨询，截至 2026 年 1 月 9 日，全国生猪均 ...

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].

格隆汇1月9日｜开源证券研报指出，生物股份为我国动保龙头，产品涵盖猪、禽、反刍、宠物四大类百 余种疫苗，常规疫苗新品多点开花持续成长，非瘟疫苗打开成长新空间。公司非瘟疫苗上市确定性逐步 增强，维持公司2025年盈利预测不变，上调2026-2027年盈利预测，预计公司2025-2027年归母净利润分 别为1.88/7.12/12.11（原2026-2027年预测分别为3.52/5.08）亿元，EPS分别为0.17/0.64/1.09元，当前股价 对应PE分别为98.5/25.9/15.3。公司非瘟疫苗全球首发在即，成长动能强劲，维持"买入"评级。 ...

Group 1 - The stock price of Bio Co., Ltd. increased by 5.06% on January 9, reaching 17.45 CNY per share, with a trading volume of 918 million CNY and a turnover rate of 4.80%, resulting in a total market capitalization of 19.4 billion CNY [1] - Bio Co., Ltd. has experienced a continuous increase in stock price for five consecutive days, with a cumulative increase of 10.73% during this period [1] - The company, established on March 13, 1993, and listed on January 15, 1999, is primarily engaged in the research, production, and sales of veterinary biological products, with main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Group 2 - E Fund's fund under management has a significant position in Bio Co., Ltd., with the E Fund CSI Modern Agriculture Theme ETF (562900) increasing its holdings by 19,600 shares in the third quarter, totaling 239,100 shares, which accounts for 2.79% of the fund's net value, ranking it as the eighth largest holding [2] - The estimated floating profit from the recent stock price increase is approximately 200,800 CNY, with a total floating profit of 385,000 CNY during the five-day increase [2] - The E Fund CSI Modern Agriculture Theme ETF (562900) was established on December 2, 2021, with a latest scale of 82.62 million CNY, and has reported a year-to-date return of 0.38%, ranking 5235 out of 5509 in its category [2]

2025 年 10 月底，开源证券给出的 2025 - 2027 年归母净利润预测分别为 1.88 亿元、3.52 亿元和 5.08 亿 元，那时的判断还相对谨慎。然而，仅仅两个多月后的 2026 年 1 月 8 日，最新报告横空出世，2025 年 预测维持不变，可 2026 - 2027 年预测却大幅上调至 7.12 亿元和 12.11 亿元。2026 年预测值近乎翻番， 2027 年预测值更是增长超 138%，这调整幅度，就像坐了火箭，令人咋舌。 二、非瘟疫苗：核心驱动的"王炸" 这一重大调整，关键在于非洲猪瘟亚单位疫苗研发的超预期进展。2025 年 7 月，生物股份成为国内首 家获批开展非瘟亚单位疫苗临床试验的企业，而且还是唯一承担单位，这独一份的"特权"，就像拿到了 通往财富宝藏的钥匙。截至 2025 年 12 月底，首轮攻毒试验已经启动，疫苗有望在 2026 年下半年至 2027 年上市。开源证券保守估计，非瘟疫苗在国内可能带来约 84 亿元的增量市场规模，生物股份凭借 先发优势，无疑将成为这场财富盛宴的最大受益者之一。 在资本市场，时间就是试金石，短短不到三个月，开源证券对生物股份（600201. ...

Group 1 - South Africa is experiencing the most severe foot-and-mouth disease outbreak in its history, with rapid virus transmission and strong infectivity, posing an unprecedented disaster for the livestock industry [1] - The outbreak began in April 2025 in KwaZulu-Natal province and has spread to other key agricultural areas, prompting the South African Department of Agriculture to procure vaccines for emergency vaccination of 930,000 animals [1] - The outbreak highlights the importance of global animal disease prevention and presents overseas market expansion opportunities for domestic animal health companies with technological advantages [1] Group 2 - The animal health industry has a tightly linked upstream and downstream, with upstream raw material drug companies providing essential support for vaccine production, while downstream demand from farming recovery and overseas epidemic prevention needs drive industry growth [2] - Companies like Reap Bio focus on veterinary biological products, including foot-and-mouth disease vaccines, covering multiple sectors such as pigs, poultry, and pets [3] - Bio Company is a leading domestic animal health enterprise with designated production qualifications for strong immunity foot-and-mouth disease vaccines, consistently ranking first in the industry for vaccine batch approvals [4]

Group 1: AI Chip Industry - The AI chip market in China is projected to grow from CNY 142.54 billion in 2024 to CNY 1,336.79 billion by 2029, driven by government support and technological advancements in the domestic AI industry [5][6]. - The domestic AI industry is categorized into three stages: the first focuses on self-sufficient AI computing, storage, and power chips; the second on chip manufacturing processes like wafer fabrication and packaging; and the third on foundational technologies such as materials and EDA [6][8]. - Key players in the AI chip market include Huawei, Cambricon, and Haiguang Information, with significant growth expected in AI storage and computing chips [6][7]. Group 2: Banking Sector - The banking sector is expected to see a steady growth of CNY 3.8 trillion in wealth management products by 2026, with a year-on-year increase of 11.46% [11]. - The demand for short-term wealth management products is rising, particularly non-current management products with a duration of less than one month, which are expected to yield annualized returns close to 3-year fixed deposit rates [12]. - Major banks like Citic Bank and Everbright Bank are recommended for their diversified product lines and strong research capabilities, while other banks such as SPDB and Bank of Beijing are also seen as beneficiaries [15]. Group 3: High-end Membrane Materials - The Chinese high-end membrane materials industry is poised for rapid growth due to geopolitical tensions and the shift of the global optoelectronic industry towards China, with a focus on breaking Japan's technological monopoly [19][20]. - Key domestic companies in this sector include Dongcai Technology and Jiemai Technology, which are expanding their production capacities and entering supply chains of major clients [20]. - The market for optical films and release films is characterized by high technical barriers, with significant opportunities for domestic manufacturers to capture market share from established foreign competitors [20][21]. Group 4: Semiconductor Equipment and Materials - The semiconductor materials and equipment sector is expected to accelerate its domestic capabilities due to increased geopolitical risks and supply chain security concerns, with a focus on self-sufficiency [29][30]. - Key areas for growth include photoresists and coating equipment, where domestic companies are beginning to establish a foothold in high-end markets [31][32]. - Beneficiaries in this sector include companies like Tongcheng New Materials and Changchuan Technology, which are positioned to capitalize on the growing demand for domestic semiconductor solutions [33]. Group 5: Animal Health Industry - The company is a leading player in the animal health sector, with a strong pipeline of vaccines, including the upcoming launch of a novel African swine fever vaccine, which is expected to significantly enhance profitability [34][36]. - The company has a robust R&D framework, with a focus on innovation and a diverse range of vaccine products, which positions it well for future growth [35]. - The anticipated market for the African swine fever vaccine could reach CNY 8.4 billion annually, providing a substantial growth opportunity for the company [36].